Reporting Before Mandate: Why Illinois Needs Real 340B Transparency First

Reporting Before Mandate: Why Illinois Needs Real 340B Transparency First

by John Conrad | May 27, 2026 | iBIO in the News, Policy News

Yesterday in Springfield, iBIO President and CEO John Conrad testified on legislation that would expand and reshape how Illinois interacts with the federal 340B drug discount program-underscoring a principle iBIO believes must come first: independent, enforceable reporting.

The 340B program was created to help certain low-income and uninsured patients access medicines by requiring participating drug manufacturers to provide discounts to eligible hospitals and clinics. That mission is important, and iBIO supports policies that protect access for vulnerable patients.

But as the debate over 340B intensifies in Illinois and across the country, one reality is unavoidable: this is a multi-billion dollar program with powerful financial incentives-and far too little standardized transparency about where the dollars go and what outcomes they produce.

In his testimony, Conrad urged lawmakers to put oversight before expansion:

"We should not alter a multi-billion dollar federal program affecting patients, employers, taxpayers without clear and forcible independent reporting in place."

Why reporting has to come first

Healthcare policy works best when it is grounded in facts. When large sums of money flow through complex systems-providers, payers, employers, taxpayers-public trust depends on whether stakeholders can answer basic questions with confidence.

Right now, too much of the 340B conversation is happening without consistent, independently verifiable data on the core issues policymakers should be evaluating:

• Where are the savings going?
• Who is benefiting-patients, systems, or intermediaries?
• What outcomes are being achieved for patients and communities?
• What are the cost impacts on employers and taxpayers?

Without credible reporting requirements, any effort to expand or mandate new structures around 340B risks scaling a system that lacks the guardrails needed to ensure it is delivering on its original purpose.

Accountability and access go together

iBIO's message is straightforward: protecting patients and protecting public confidence are not competing goals. They are linked.

Strong reporting doesn't undermine 340B-it strengthens it. It creates a foundation for reforms that are fair, targeted, and measurable. It helps distinguish between policies that genuinely improve access and those that primarily shift costs or create unintended incentives.

If Illinois is going to make major policy decisions affecting patients, employers, and taxpayers, lawmakers deserve a clear picture of how the program operates today-supported by independent, enforceable reporting-before moving forward with expansion.

iBIO will keep engaging

iBIO will continue working with lawmakers, stakeholders, and members to advance solutions that improve patient access while ensuring transparency, accountability, and responsible stewardship of healthcare dollars.

As this legislation moves, iBIO will keep advocating for the principle that should guide any serious 340B reform:

Reporting before mandate.

Related coverage:

https://www.thecentersquare.com/illinois/article_e464c194-d30f-4c01-b29e-7bc0efd6c14f.html